Skip to main content
SpringerLink
Log in

Are higher doses of rifaximin more effective for the treatment of small-intestinal bacterial overgrowth?

  • Practice Point
  • Published:

From Nature Clinical Practice Gastroenterology & Hepatology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kalser MH et al. (1966) Normal viral and bacterial flora of the human small and large intestine. N Engl J Med 274: 500–505

    Article  CAS  Google Scholar 

  2. Riordan SM (1996) A critical appraisal of diagnostic tests for small intestinal bacterial overgrowth. Gastroenterol Internat 9: 110–119

    Google Scholar 

  3. Riordan SM et al. (1995) Bacteriologic analysis of mucosal biopsy specimens for detecting small-intestinal bacterial overgrowth. Scand J Gastroenterol 30: 681–685

    Article  CAS  Google Scholar 

  4. King CE and Toskes PP (1986) Comparison of the 1-gram 14C-xylose, 10-gram lactulose-H2 and 80-gram glucose-H2 breath tests in patients with small intestine bacterial overgrowth. Gastroenterology 91: 1447–1451

    Article  CAS  Google Scholar 

  5. Corazza GR et al. (1990) The diagnosis of small bowel bacterial overgrowth. Reliability of jejunal culture and inadequacy of breath hydrogen testing. Gastroenterology 98: 302–309

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Rachel Jones, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Professor of Gastroenterology and the Acting Chairman Department of Gastroenterology at the University Hospital, Basel, Switzerland

    Christoph Beglinger

  2. Assistant Professor of Gastroenterology, in the Department of Gastroenterology at the University Hospital, Basel, Switzerland

    Lukas Degen

Authors
  1. Christoph Beglinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lukas Degen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christoph Beglinger.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Beglinger, C., Degen, L. Are higher doses of rifaximin more effective for the treatment of small-intestinal bacterial overgrowth?. Nat Rev Gastroenterol Hepatol 3, 22–23 (2006). https://doi.org/10.1038/ncpgasthep0371

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpgasthep0371

  • Springer Nature Limited

Search

Navigation